Lumos Pharma, Inc.
Index- P/E- EPS (ttm)-3.43 Insider Own9.70% Shs Outstand8.37M Perf Week1.13%
Market Cap74.30M Forward P/E- EPS next Y-3.86 Insider Trans0.37% Shs Float5.60M Perf Month4.57%
Income-28.70M PEG- EPS next Q-1.01 Inst Own28.70% Short Float4.46% Perf Quarter15.82%
Sales0.70M P/S106.14 EPS this Y-291.90% Inst Trans-4.06% Short Ratio27.83 Perf Half Y-9.43%
Book/sh8.91 P/B1.00 EPS next Y0.00% ROA-29.80% Target Price23.33 Perf Year-9.16%
Cash/sh9.56 P/C0.93 EPS next 5Y15.20% ROE-33.80% 52W Range6.15 - 10.57 Perf YTD28.86%
Dividend- P/FCF- EPS past 5Y32.70% ROI-34.50% 52W High-15.56% Beta1.15
Dividend %- Quick Ratio17.60 Sales past 5Y-63.60% Gross Margin- 52W Low45.20% ATR0.36
Employees32 Current Ratio17.60 Sales Q/Q3930.00% Oper. Margin- RSI (14)59.51 Volatility5.12% 3.50%
OptionableNo Debt/Eq0.00 EPS Q/Q5.60% Profit Margin- Rel Volume0.81 Prev Close9.00
ShortableYes LT Debt/Eq0.00 EarningsAug 09 AMC Payout- Avg Volume8.97K Price8.93
Recom1.70 SMA203.26% SMA506.04% SMA2007.34% Volume7,255 Change-0.78%
Mar-11-21Upgrade Stifel Hold → Buy $4 → $24
Dec-03-20Initiated Cantor Fitzgerald Buy $32
Aug-26-20Initiated Piper Sandler Overweight $26
Aug-17-20Resumed ROTH Capital Buy $51
Aug-04-20Initiated H.C. Wainwright Buy $33
Sep-26-22 04:05PM
Aug-31-22 09:00AM
Aug-16-22 07:30AM
Aug-09-22 04:01PM
Jul-27-22 04:05PM
08:27AM Loading…
Jul-24-22 08:27AM
Jul-20-22 08:32PM
May-16-22 04:05PM
May-10-22 04:01PM
May-06-22 10:25AM
May-05-22 09:00AM
Apr-26-22 09:00AM
Apr-11-22 08:30AM
Mar-23-22 04:05PM
Mar-10-22 04:01PM
09:00AM Loading…
Feb-23-22 09:00AM
Feb-14-22 12:05PM
Jan-05-22 09:00AM
Dec-28-21 09:38AM
Dec-21-21 09:38AM
Dec-16-21 09:38AM
Dec-08-21 09:38AM
Nov-24-21 10:00AM
Nov-15-21 11:14AM
Nov-10-21 05:06PM
Nov-08-21 10:42AM
Nov-03-21 04:01PM
Oct-21-21 04:05PM
Sep-02-21 08:00AM
09:58AM Loading…
Aug-16-21 09:58AM
Aug-05-21 08:00AM
Aug-03-21 08:00AM
Aug-02-21 08:00AM
Jul-26-21 04:18PM
Jul-22-21 08:00AM
Jul-20-21 04:01PM
Jun-28-21 08:00AM
May-19-21 09:00AM
May-13-21 09:00AM
May-05-21 04:01PM
Apr-28-21 09:00AM
Apr-27-21 08:00AM
Apr-20-21 04:05PM
Apr-14-21 04:05PM
Mar-20-21 11:00AM
Mar-11-21 04:05PM
Mar-09-21 04:05PM
Mar-04-21 09:00AM
Mar-02-21 04:05PM
Feb-22-21 04:15PM
Feb-16-21 04:01PM
Dec-18-20 09:00AM
Dec-16-20 02:19AM
Nov-30-20 05:35PM
Nov-23-20 07:43PM
Nov-10-20 04:01PM
Nov-03-20 12:30PM
Oct-29-20 09:00AM
Oct-27-20 04:01PM
Aug-27-20 09:00AM
Aug-13-20 04:01PM
Jul-28-20 04:01PM
Jul-27-20 04:05PM
Jun-19-20 08:21AM
Jun-10-20 03:41PM
May-28-20 04:01PM
May-27-20 04:27PM
May-26-20 10:36AM
Apr-24-20 08:00AM
Apr-02-20 04:05PM
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hawkins Richard JChief Executive OfficerSep 23Buy8.802081,8304,469Sep 23 05:05 PM
Hawkins Richard JChief Executive OfficerSep 21Buy8.842,21419,5724,261Sep 23 05:05 PM
Hawkins Richard JChief Executive OfficerSep 20Buy8.751,50613,1782,047Sep 21 06:45 PM
Hawkins Richard JChief Executive OfficerSep 19Buy8.655414,680541Sep 21 06:45 PM
Raffin Thomas A.DirectorAug 25Buy8.461,1509,7299,406Aug 26 05:00 PM
McCracken Joseph SDirectorAug 25Buy8.603,17027,26211,721Aug 26 04:59 PM
McKew John C.Chief Scientific OfficerAug 02Sale8.113,40727,63124,602Aug 03 11:25 AM
McKew John C.Chief Scientific OfficerJun 06Sale7.621691,28829,102Jun 07 04:23 PM
McKew John C.Chief Scientific OfficerApr 05Sale8.322,21418,42029,271Apr 05 05:29 PM